Active U.S. drug shortages increased to 227 in the second quarter of 2026, marking the third consecutive quarterly increase, according to the American Society of Health-System Pharmacists. Nearly half of all new shortages this year involve medications made by a single manufacturer, a concentration that increases supply chain vulnerability, and the FDA’s database continues to reflect new discontinuations weekly.
The database is updated daily to reflect manufacturing recoveries, regulatory actions and how shortages are classified, not solely day-to-day availability at the hospital level.
Here are nine recent drug shortages, according to the FDA database:
- Triamcinolone acetonide injection: Harrow Eye resolved the shortage of its Triesence 40-milligram/1-milliliter presentation of the ophthalmic corticosteroid July 31, closing out a shortage that had been active since September 2021.
- Doxycycline hyclate delayed-release tablet: Teva Pharmaceuticals discontinued its 50-milligram and 200-milligram presentations of the antibiotic July 30.
- Glycopyrrolate injection: Fresenius Kabi discontinued four presentations of the anesthesia drug, ranging from 0.2-milligram/1-milliliter to 1-milligram/5-milliliter, July 30.
- Lidocaine hydrochloride injection: Anthea Pharma added six presentations of the local anesthetic, distributed by Avenacy, to the market July 30. The ingredient remains in shortage overall, with Eugia and Fresenius Kabi reporting several presentations on backorder due to demand increases, some with recovery dates not expected until mid- to late August.
- Fluticasone propionate and salmeterol xinafoate aerosol, metered: GlaxoSmithKline is discontinuing three Advair HFA presentations (45/21, 115/21 and 230/21 micrograms) July 27, with distribution expected to cease by around December 31. The 120-dose presentation of the inhaler will remain available.
- Lopinavir and ritonavir oral solution: AbbVie discontinued its Kaletra 80-milligram/20-milligram-per-milliliter oral solution July 24.
- Lopinavir and ritonavir tablet: AbbVie also discontinued four Kaletra tablet presentations, in 100-milligram/25-milligram and 200-milligram/50-milligram strengths, July 24.
- Ritonavir oral powder: AbbVie discontinued its Norvir 100-milligram oral powder presentation of the antiretroviral July 24.
- Ritonavir tablet: AbbVie discontinued its Norvir 100-milligram tablet presentation July 24, rounding out four related HIV antiretroviral discontinuations tied to the Kaletra and Norvir product lines.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.